News
Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
1don MSN
In the first quarter, the Frito-Lay maker posted its first quarterly profit miss in at least five years. PepsiCo's revenue ...
Netflix had success with "Squid Game" in the second quarter, but investors and analysts want to know what's next outside the ...
Many Wall Street analysts keep boosting their stock price target as the streaming giant's shares have gained around 40 ...
3d
Zacks Investment Research on MSNHow Will Pfizer's Oncology Drugs Perform in Q2 Earnings?Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...
Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure.
1h
Zacks Investment Research on MSNThermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline EstimatesAnalysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year.
Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.
Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results